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Introduction 25
Bronchiectasis is a chronic inflammatory lung disease characterised by recurrent cough, sputum 26 production and recurrent respiratory tract infections.(1) Failure of the mucociliary escalator and 27 innate antimicrobial defences leads to chronic bacterial colonisation of the airways.(2) Bacteria 28 provoke an inflammatory response that can further drive airways inflammation and airway 29 structural damage leading to the well described "vicious cycle" of bronchiectasis.(2,3) 30
While the majority of patients with bronchiectasis may be colonised with organisms that are upper 31 airway commensals such as Haemophilus influenzae and Streptococcus pneumoniae, a proportion of 32 patients become colonised with the opportunistic pathogen Pseudomonas aeruginosa.(4-6) 33
In cystic fibrosis (CF) bronchiectasis, it is well established that P. aeruginosa colonisation leads to a 34 more rapid deterioration in lung function and earlier mortality.(7) Consequently, P. aeruginosa 35 eradication is standard care in European CF centres. (8, 9) The capability of P. aeruginosa to form 36 biofilms provide it with physical and chemical protection from the immune system and reduces its 37 exposure to systemically delivered antibiotics.(10,11) P. aeruginosa has the ability to rapidly adapt to 38 chronic infection in the lung and readily develops antimicrobial resistance. Management of P. 39 aeruginosa therefore represents a significant clinical challenge. 40
In bronchiectasis, conflicting data have been published on the independent contribution of P. 41 aeruginosa to long term prognosis and there remains a question of whether P. aeruginosa drives 42 disease progression or is simply a marker of existing severe disease.(12,13) Determining the 43 importance of P. aeruginosa to bronchiectasis morbidity and mortality is important, as there are few 44 evidence based treatments for bronchiectasis.(14) Current therapeutic development is heavily 45 influenced by CF and is therefore largely targeted towards treatment of P. aeruginosa 46 infection.(15,16) Therefore from clinical, drug development and regulatory perspectives it is 47 important to have a comprehensive understanding of the impact of P. aeruginosa on outcomes in 48 bronchiectasis. 49
We therefore undertook a systematic review to determine whether colonisation with P. aeruginosa 50 influences future prognosis and/or is associated with cross-sectional features of severity. 51 5
METHODS 53
The present study was a systematic review and meta-analysis conducted and reported according to 54 MOOSE (meta-analysis of observational studies in epidemiology) guidelines.(17) 55
Search Criteria 56
The study was based on a search of the PUBMED database for articles evaluating the prognostic 57 impact of colonisation with P. aeruginosa. The following search strategy was used: ("Pseudomonas" 58 OR "aeruginosa") AND ("bronchiectasis") followed by ("prognosis" or "mortality") and 59 ("bronchiectasis"). The search included articles published between January 1980 and January 2015. 60
No language criteria were applied. Full articles of potentially appropriate abstracts were reviewed. 61
Only peer reviewed data were included. Conference abstracts were excluded. The search was 62 repeated in EMBASE and Web of Science to obtain any articles missed by the initial search. The 63 search strategy was supplemented by reviewing of the reference lists, bibliographies including the 64 British Thoracic Society guidelines and investigator files. 65 66
Data extraction 67
Non relevant studies were excluded based on review of the title and abstract. Article reviewing was 68 performed independently by two investigators ((two out of SF, ,MM, AHL, SA and JC) who conducted 69 data extraction and quality assessment from studies meeting the inclusion criteria. All investigators 70 have experienced of meta-analysis and training in literature review. Any disagreement between 71 investigators was resolved independently by a third investigator. Additional unpublished data were 72 obtained from study authors where possible. Where data were presented only as medians, means 73 with standard deviation were estimated according to the formula of Hozo et al. (18)  74 6
Study inclusion and exclusion criteria 77
All studies were considered eligible if they fulfilled the following criteria: original publications; 78 inclusion of a cohort of patients with computed tomography diagnosed bronchiectasis not due to 79 cystic fibrosis; inclusion of patients with P. aeruginosa colonisation and a comparator population 80 without P. aeruginosa colonisation; reporting of one of the study outcomes which were determined 81 a priori (described below). 82
Definitions of P. aeruginosa colonisation were obtained from the source studies and were not pre-83 specified. 84
As the aim of this study was to compare P. aeruginosa colonised patients compared to non-85 colonised patients, we excluded any studies which provided data only for a single population. We 86 also excluded case reports; review articles, editorials and letters without original data. 87
88

Study outcomes 89
Primary analysis 90
Our hypothesis was that P. aeruginosa colonisation would be associated with globally worse clinical 91 outcome when compared to patients without P. aeruginosa colonisation. Outcomes were split into 92 longitudinal clinical outcomes determined during follow-up, and cross-sectional outcomes. The 93 primary longitudinal outcome was all-cause mortality. Secondary outcomes were: hospital 94 admissions, exacerbation frequency, decline in forced expiratory volume in 1 second (FEV1) and the 95 prognostic impact of P. aeruginosa eradication therapy. 96
Cross sectional outcomes were: FEV1 % predicted, forced vital capacity (FVC), radiological 97 involvement and quality of life (QoL). A descriptive analysis of the methods of defining P. aeruginosa 98 colonisation in the literature was also considered a pre-specified secondary end-point. 99 7 Anticipating that studies would have different lengths of follow-up to determine survival, we pre-100 specified that data could be pooled where equal follow-up was demonstrated between P. 101 aeruginosa colonised and non-colonised patients. 102
Quality assessments 104
The quality of each study was independently assessed according to the criteria described by Hayden 105 et al, which are widely used for assessing the quality of observational studies in meta-106 analysis. (19, 20) The agreement between the two reviewers (two of SF, AHL and JC) was measured 107 using the kappa statistic. Publication bias was determined by visual inspection of funnel plots and 108 Eggers test. 109 110
Sensitivity analysis 111
A priori we identified possible factors that may be major sources of bias and planned subanalyses for 112 the follow; 1) Analysis according to different definitions of P. aeruginosa colonisation e.g single 113 isolate versus multiple isolatins; 2) Comparison of P. aeruginosa vs H. influenzae colonised patients 114 compared to comparisons of P. aeruginosa colonised vs non-colonised patients; 3) Data derived 115 from high quality and prospective studies. 116 117
Statistical analysis 118
The primary outcome of the relationship between P. aeruginosa colonisation and mortality was 119 displayed as odds ratios (OR) with 95% confidence intervals (95% CI). ORs were pooled using a 120
Mantel-Haenszel random effects model. The same analysis was used for hospital admissions. 121 8 Continuous variables such as quality of life, lobar involvement, pulmonary function tests and 122 exacerbations were compared by pooling mean differences by the inverse of their variance. As 123 above, random effects meta-analysis was used due to expected heterogeneity between studies. To 124 analyse for possible effect modifiers, such as study quality or definitions of colonisation, we 125 compared OR's using interaction testing as described. The results of the literature review are shown in figure 1 . The majority of studies were rejected 138 because they did not deal specifically with patients with bronchiectasis not due to CF or did not 139 evaluate severity or outcomes. Of 55 articles selected as relevant, 21 studies had valid data for 140 inclusion and were pooled in the meta-analysis.(6,12,13,21-36) One study contained data for 5 141 cohorts and each cohort was considered separately for the purposes of this analysis on the basis that 142 they were independent cohorts (total 25 cohorts).(24) 143 9 Characteristics of the 21 included studies are shown in table 1. 10 studies were from the UK 146 (12,21,23,24,26,28,31,32) and overall 16 cohorts were from Europe. There were no cohorts from 147 aeruginosa ranged from 7.7% at 1 year, 13.6% at 2 years to 30-50% at 5 years. Corresponding 165 mortality rates for patients without P. aeruginosa were 0% at 1 year, 7% at 2 years and 9-15% at 5 166 years. All studies showed a higher risk of mortality associated with P. aeruginosa colonisation. The 167 pooled OR for mortality was 2.95 (95% CI 1.98-4.40; p<0.0001). Heterogeneity tests were not 168 statistically significant. This is shown in figure 2 . 169 10 Sub-analyses confirmed this association in high quality studies (OR 3.64, 95% CI 1.75-7.55; p=0.0005, 170 n=1433), prospective studies and excluding studies with <3 (OR 2.82, 95% CI 1.94-4.11; p<0.0001, 171 n=1994) and >6 years follow-up (OR 3.14, 95% CI 1.83-5.33; p<0.0001, n=1894). 172 173
Hospital admissions 174
This analysis included 7 cohorts with 1628 participants (23,24,29). Hospital admission rates for 175 patients with P. aeruginosa varied from 41% at 1 year to 75% at 4 years. Corresponding hospital 176 admission rates in patients without P. aeruginosa were 15% at 1 year and 28.5% at 4 years. P. 177
aeruginosa was associated with a marked increase in the risk of hospital admissions -pooled OR 178 6.57 (95% CI 3.19-13.51; p<0.0001). There was significant heterogeneity which was not resolved on 179
limiting studies by quality, prospective design or length of follow-up. Insufficient data was available 180 to evaluate additional impacts such as length of hospital stay or economic impacts of hospitalisation. 
Cross sectional association between P. aeruginosa and markers of severe disease 208
Patient characteristics 209
In cross-sectional studies we observed that patients with P. aeruginosa infection were on average 3 210 years older than non-colonised patients (mean difference 3.1 years, 95% CI 0.9-5.4,p=0.007, I 2 =48%). 211
Interestingly there was a statistically significant association between male gender and P. aeruginosa 212 colonisation, OR 1.39 95% CI 1.09-1.75, p=0.009, I 2 =0%. 213
Quality of life 214
The only data that were available for QoL used the St.Georges Respiratory Questionnaire (SGRQ). 215
The SGRQ is a validated questionnaire in patients with bronchiectasis that has been widely used with 216 an accepted increment of 4 points demonstrating clinical significance.(37) 4 studies reported data 217 for SGRQ, with a mean difference of 18.2 points (95% CI 14.7-21.8; p<0.0001, n=1041).(22,24,28) 218
There was no heterogeneity between studies (I 2 =0%). No data were available for other 219 questionnaires, including the QoL-Bronchiectasis questionnaire. 220 221
Lung Function-FEV1 and FVC 222
As expected, patients with P. aeruginosa colonisation had worse cross-sectional lung function 223 compared to patients without P. aeruginosa. 17 studies reported valid data for FEV1 with all showing 224 worse lung function in the P. aeruginosa group ranging from -1.4% to -29%. 225 (6,12,13,21,22,24,28,29,30,31,33,34,36) The pooled mean difference was 15.0% (95% CI -18.7 to -226 11.3; p<0.0001). There was significant heterogeneity but this was no longer statistically significant 227 after excluding 1 study that defined P. aeruginosa presence by PCR.(6) 9 cohorts presented data for 228 FVC with a pooled mean difference of -9.4% (95% CI -14.3 to -4.5%;p=0.005, n=1453). 229 (12,24,28,29,33,34) 230 231
Radiological severity 232
Although multiple severity scoring systems have been utilised in bronchiectasis, the only variable 233 which was studied in more than one study was the number of lobes involved on CT. This data were 234 available in 9 cohorts. (24,29,30,32,34,35) The mean difference between P. aeruginosa colonised and 235 non-colonised was 1.4 lobes (95% CI 0.93-1.86; p<0.0001). Nevertheless all studies reported worse 236 radiological severity in P. aeruginosa colonised patients. 237
Sensitivity analyses 238
Limiting the analysis to only those studies that used the most robust definition of P. aeruginosa 239 colonisation, requiring at least 2 positive sputum samples over a 12 month period, showed very 240 13 similar results to the primary analysis with ORs for mortality of 3.46, 95% CI 1.96-.6.08; p<0.0001; 241 hospital admissions 7.22, 95% CI 2.88-18.09; p<0.0001 and exacerbations mean difference 0.87, 95% 242 CI 0.59-1.15; p<0.0001 (p>0.5 when comparing odds ratios using interaction testing compared to the 243 overall cohort). 244 245 8 cohorts provided data that could be used to directly compare the outcomes of patients colonised 246 with P. aeruginosa versus Haemophilus influenzae. The findings were highly consistent with the main 247 analysis, with an increase in mortality associated with P. aeruginosa (OR 4.00, 95% CI 2.28-7.02; 248 p<0.001), increased rate of hospital admissions (OR 6.75, 95% CI 3.98-11.45; p<0.001), increased 249 exacerbations (mean difference 0.99 (95% CI 0.54-1.43; p<0.0001) and low FEV1 (mean difference -250 11.4, 95% CI -14.8 to -7.9; p<0.0001). in bronchiectasis is important for clinicians, for drug developers and for regulators. This analysis 258 provides a detailed insight into the impact that P. aeruginosa colonisation has on key clinical 259 outcomes in bronchiectasis. In addition, P. aeruginosa colonisation was associated with multiple 260 cross-sectional markers of disease severity. It can therefore be said that P. aeruginosa is both a 261 marker of severe disease, and is associated with a worse long term prognosis. Bronchiectasis has 262 historically been a neglected condition, described in the ERS white book as one of the most 263 neglected diseases in respiratory medicine.(40) As a result, there have been few large cohort studies. 264
The value of meta-analysis therefore is to combine the available data from existing small studies to 265 give a more accurate estimate of the disease impact. 266
The most striking finding within this analysis is the impact of P. aeruginosa on all-cause mortality. 267
Our analysis identifies a 3-fold increase in the risk of death with P. aeruginosa colonisation. P. representative registries for patients with bronchiectasis are needed internationally. Few studies 306 examining lung function decline were identified, and those that were found were small with 307 inconsistent results. We would recommend further large studies of lung function decline in 308 bronchiectasis. There is a lack of data describing the impact of organisms other than P. aeruginosa in 309 bronchiectasis and in particular comparing the outcomes of P. aeruginosa colonised patients with 310 those colonised with the most common bronchiectasis pathogens such as H. influenzae or Moraxella 311 catarrhalis. Such data would be valuable as recent reports suggest that these patients do have a 312 worse outcome compared to non-colonised patients, but to a lesser extent than P. aeruginosa.(24) 313
For example in the Bronchiectasis Severity Index, 3 points are awarded to patients with P. 314 aeruginosa colonisation and 1 point to patients colonised with other pathogens.(24) For this meta-315 analysis, we were able to identify 8 cohorts with data to compare outcomes between P. aeruginosa 316 and H. Influenzae colonised patients and these confirmed the significantly worse clinical outcomes 317 associated with P. aeruginosa. 318
There is a need from both a clinical and research perspective to define chronic bacterial colonisation 319 in bronchiectasis as this analysis identified 8 different methods of defining P. aeruginosa 320 colonisation in bronchiectasis studies. The most frequently used definition was 2 or more positive 321 cultures at least 3 months apart in 12 months. This should be standardised across studies to increase 322 our ability to generalise results between studies and healthcare systems. Our data were almost 323 entirely based on traditional bacterial culture and recent studies have increasingly used quantitative 324 PCR or characterisation of the microbiome through sequencing of the 16s ribosomal RNA subunit to 325 determine bacterial colonisation status.(6,36,44) This method is significantly more sensitive for the 326 detection of P. aeruginosa with Rogers et al. demonstrating very poor correlation between culture 327 and PCR for P. aeruginosa detection: 91/107 patients in this study were positive for P. aeruginosa 328 versus 31/107 by culture.(6) For this reason, further studies of the role of PCR in P. aeruginosa 329 detection and to confirm eradication, would be beneficial. 330
The word colonisation in this context is perhaps misleading. Colonisation implies a benign state 331 defined by absence of tissue invasion or tissue damage. The term 'chronic infection' may be more 332 appropriate given the clearly established association between the presence of bacteria and airway 333 inflammation and the worse clinical outcomes observed in the presence of P. aeruginosa. 334
335
In summary, P. aeruginosa colonisation is associated with increased mortality, hospital admissions 336 and exacerbations, and is associated with worse QoL. As such, new Isolation of P. aeruginosa should 337 be considered a highly significant clinical event and followed up with repeated cultures and attempts 338 to eradicate in line with guideline recommendations. 339 
